Abstract
BackgroundThe study shows the role of PET/CT in monitoring response to therapy in colorectal cancer as well as detection of loco-regional recurrence and metastatic deposits hence guiding the clinician to the proper management strategy. Sixty patients (41male and 19 female) were included in our study. All patients are pathologically proven colorectal cancer. They had undergone 18F-FDG PET/CT for follow up post-therapeutic (operative, and/or chemotherapy and/or radiotherapy) follow up for metastatic or recurrent colorectal cancer during the period from September 2015 to August 2017.ResultsOur study demonstrated that FDG PET/CT is highly sensitive and specific in assessing local recurrence and distant metastasis in patient with pathologically proved colorectal cancer, with sensitivity 95.45%, specificity 97.3%, and accuracy 96.7% in detection of local recurrence; and sensitivity, specificity, and accuracy of 100% in detection of hepatic metastasis as well as in detection of nodal metastasis.ConclusionFDG PET/CT is an accurate modality in the treatment plan of cancer colon in monitoring therapeutic response as well as defining their local extent and distant metastatic disease thus provides valuable information that is very helpful in the clinical decision-making process.
Highlights
The study shows the role of positron emission tomography (PET)/computed tomography (CT) in monitoring response to therapy in colorectal cancer as well as detection of loco-regional recurrence and metastatic deposits guiding the clinician to the proper management strategy
Aim of the work The aim of this study is to show the role of PET/CT in monitoring the response to the therapy in colorectal cancer as well as the detection of loco-regional recurrence and metastatic deposits, guiding the clinician to the proper management strategy
We agree with that as our study showed that PET/CT sensitivity and specificity in detecting regional lymph node are 100%; this not going with Sung Hoon Kim et al [30] who demonstrated that nodal [18F] FDG uptake findings were highly specific for LN metastases status, but it had a relatively low sensitivity; this low sensitivity in this study was attributed to the fact that the later study excluded the patients who had received neoadjuvant treatment and they stated that I if these advanced rectal cancer patients who underwent neoadjuvant chemotherapy were included in the present study, the LN detectability of [18F]FDG PET/CT may be improved because the majority of these patients have shown high nodal [18F]FDG uptake
Summary
The study shows the role of PET/CT in monitoring response to therapy in colorectal cancer as well as detection of loco-regional recurrence and metastatic deposits guiding the clinician to the proper management strategy. All patients are pathologically proven colorectal cancer. They had undergone 18F-FDG PET/CT for follow up post-therapeutic (operative, and/or chemotherapy and/or radiotherapy) follow up for metastatic or recurrent colorectal cancer during the period from September 2015 to August 2017. Risk factors for CRC include dietary, hereditary, and environmental influences [4], which lead to the gradual accumulation of genetic mutations and epigenetic alterations that drive the development of tumors over decades [5]. Advances in our ability to detect developing CRC has begun to refine the prognostic information available and define patient groups that are likely to benefit from systemic treatment or targeted therapies [7]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
